Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) insider Heidy King-Jones sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $90.00, for a total transaction of $36,000.00. Following the completion of the transaction, the insider directly owned 2,845 shares of the company’s stock, valued at $256,050. This trade represents a 12.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heidy King-Jones also recently made the following trade(s):

• On Tuesday, September 1st, Heidy King-Jones sold 27,999 shares of Spyre Therapeutics stock. The shares were sold at an average price of $87.31, for a total transaction of $2,444,592.69.

Spyre Therapeutics Trading Up 0.2%

Shares of Spyre Therapeutics stock opened at $87.25 on Friday. The firm’s 50 day moving average is $98.03 and its 200 day moving average is $74.53. The firm has a market capitalization of $7.67 billion, a PE ratio of -44.74 and a beta of 2.99. Spyre Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $110.18.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.40. As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -2.62 earnings per share for the current year.

Spyre Therapeutics News Roundup

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Management plans to participate in the Citi BioPharma Back to School Conference on September 9, the Wells Fargo Healthcare Conference on September 10, and the Stifel Immunology and Inflammation Forum on September 23. These events may offer updates on Spyre’s immunology programs and development strategy, potentially providing a near-term catalyst. Spyre Therapeutics to Participate in Upcoming September Investor Conferences
• Neutral Sentiment: The company’s CEO, CFO and insider Heidy King-Jones collectively reported selling approximately 69,000 shares on September 1–2. The transactions were conducted under pre-arranged Rule 10b5-1 trading plans, making them less reliable as discretionary signals about management’s current view of Spyre’s prospects.
• Negative Sentiment: The insider transactions may nevertheless weigh on sentiment. CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold 25,732 shares across two transactions, and King-Jones sold 28,399 shares. Burrows said his sales were intended to cover tax-withholding obligations related to vested equity awards, but King-Jones’s sales substantially reduced her remaining stake. Spyre Therapeutics Insider Selling
• Negative Sentiment: A Zacks report said SYRE has declined 16.6% since its latest earnings report, indicating continued caution after the quarterly update. Although Spyre exceeded consensus estimates with a quarterly loss of $0.36 per share versus expectations for a $0.76 loss, investors appear to be seeking additional clinical or corporate catalysts. Spyre Therapeutics Down 16.6% Since Last Earnings Report

Institutional Trading of Spyre Therapeutics

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System increased its stake in shares of Spyre Therapeutics by 9,594.0% in the second quarter. California State Teachers Retirement System now owns 5,742,912 shares of the company’s stock valued at $509,856,000 after buying an additional 5,683,670 shares during the period. RTW Investments LP grew its position in shares of Spyre Therapeutics by 15.2% during the 4th quarter. RTW Investments LP now owns 4,171,996 shares of the company’s stock worth $136,675,000 after buying an additional 550,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Spyre Therapeutics by 32.3% in the 4th quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company’s stock valued at $132,189,000 after acquiring an additional 984,344 shares in the last quarter. Perceptive Advisors LLC increased its stake in shares of Spyre Therapeutics by 23.3% in the 1st quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company’s stock valued at $190,826,000 after acquiring an additional 714,000 shares in the last quarter. Finally, Capital International Investors lifted its position in shares of Spyre Therapeutics by 46.0% during the 4th quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock valued at $114,416,000 after acquiring an additional 1,100,000 shares during the period. Institutional investors own 80.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SYRE shares. Robert W. Baird set a $120.00 price objective on Spyre Therapeutics in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft cut their price target on Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, August 26th. Wedbush reduced their price target on Spyre Therapeutics from $130.00 to $123.00 and set an “outperform” rating on the stock in a report on Wednesday, August 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday. Finally, Wolfe Research downgraded Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $109.69.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.